Health Trials

Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Single Dose, Phase 1 Study of JADE101 in Healthy Japanese and Chinese Participants

This is a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of JADE101 in healthy Japanese and Chinese participants.

Participants needed: 40
Trial details
Phase: Phase 1Age: 18-55Biological sex: AllType: InterventionalSponsor: Jade Biosciences, Inc.Updated: Jun 4, 2026Locations: 1
Eligibility criteria

Healthy male or female participants 18-55 years of age, inclusive [+4]

Harmful alcohol use [+6]

Read more
Status: Recruiting

A Phase 1 Study of JADE201 in Participants With Rheumatoid Arthritis

This is a Phase 1, first in human study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of JADE201 compared to placebo in participants with Rheumatoid Arthritis

Participants needed: 36
Trial details
Phase: Phase 1Age: 18-70Biological sex: AllType: InterventionalSponsor: Jade Biosciences, Inc.Updated: Jun 1, 2026Locations: 3
Eligibility criteria

Male and female participants 18-70 years of age, inclusive. [+4]

With the exception of RA, known history of clinically significant disease [+6]

Read more
Status: Recruiting

A Study of JADE101 in Participants With Immunoglobulin A Nephropathy

This open-label Phase 2 study will characterize the safety and efficacy of JADE101 in participants with IgA nephropathy, and the results will contribute to the overall clinical characterization of JADE101 in this patient population.

Participants needed: 30
Trial details
Phase: Phase 2Age: 18-60Biological sex: AllType: InterventionalSponsor: Jade Biosciences, Inc.Updated: May 29, 2026Locations: 7
Eligibility criteria

Male or female participants 18-60 years of age, inclusive, and of local legal co... [+7]

Secondary forms of IgAN [+11]

Read more